| FEAMX | RWMHX | FEAMX / RWMHX | |
| Total Expense Ratio | 1.65 | 0.41 | 402% |
| Annual Report Gross Expense Ratio | 1.82 | 0.41 | 444% |
| Fund Existence | 28 years | 10 years | - |
| Gain YTD | 4.650 | 2.599 | 179% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 469M | 208B | 0% |
| Annual Yield % from dividends | 1.19 | 1.38 | 86% |
| Returns for 1 year | 9.31 | 8.98 | 104% |
| Returns for 3 years | 21.49 | 31.87 | 67% |
| Returns for 5 years | -3.32 | 40.18 | -8% |
| Returns for 10 years | -38.87 | 102.06 | -38% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VTV | 198.41 | 0.73 | +0.37% |
| Vanguard Value ETF | |||
| DMAX | 26.68 | 0.01 | +0.03% |
| iShares Large Cap Max Buffer Dec ETF | |||
| AFIF | 9.44 | N/A | -0.02% |
| Anfield Universal Fixed Income ETF | |||
| KXI | 66.85 | -0.11 | -0.16% |
| iShares Global Consumer Staples ETF | |||
| BBC | 40.36 | -1.13 | -2.72% |
| Virtus LifeSci Biotech Clinical Trls ETF | |||